Phase 2 Study of Sorafenib in the Management of Liver Function Impaired Advanced Hepatocellular Carcinoma

Trial Profile

Phase 2 Study of Sorafenib in the Management of Liver Function Impaired Advanced Hepatocellular Carcinoma

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 19 Oct 2015

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Oct 2015 Planned end date changed from 1 Jul 2014 to 1 Jul 2016, as reported by ClinicalTrials.gov.
    • 13 Oct 2015 Planned primary completion date changed from 1 Jan 2014 to 1 Jan 2016, as reported by ClinicalTrials.gov.
    • 10 Sep 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top